Fort Wayne Medical Oncology and Hematology, Inc.

Fort Wayne, Indiana 46885-5099

3 studies enrolling now · 49 studies all time

What they study most

Advanced Prostate Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Anorexia, Bladder Cancer, Breast Cancer, Cachexia, Cancer, Carcinoma, Non-Small Cell Lung, Chemotherapy-induced Nausea and Vomiting, Chronic Lymphocytic Leukemia, Colorectal Cancer

Studies at this site

• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer — Recruiting now
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors — Recruiting now
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer — Recruiting now
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer — Recruiting now
• A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma — Running, not enrolling
• A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer — Completed
• A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy — Completed
• Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy — Running, not enrolling
• A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period — Running, not enrolling
• A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma — Stopped early
• First in Human Study of TORL-3-600 in Participants With Advanced Cancer — Running, not enrolling
• Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) — Stopped early
• Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma — Running, not enrolling
• SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) — Completed
• Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab — Stopped early
• Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia — Completed
• Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. — Completed
• A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer — Completed
• Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling — Status unconfirmed
• Open-Label Extension and Safety Study of Talazoparib — Completed
• An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread — Completed
• Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer — Completed
• An Open-Label Pharmacokinetics and Safety Study of Talazoparib — Completed
• A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer — Completed
• A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors — Completed
• A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer — Completed
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer — Completed
• A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC — Stopped early
• Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer — Withdrawn before enrolling
• Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer — Completed
• Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer — Completed
• O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma — Completed
• Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus — Completed
• Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer — Completed
• PS-341 in Treating Patients With Metastatic Kidney Cancer — Completed
• BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer — Completed
• ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck — Completed
• SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy — Completed
• Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer — Completed
• Oxaliplatin in Treating Patients With Metastatic Bladder Cancer — Completed
• SU5416 in Treating Patients With Malignant Mesothelioma — Completed
• SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer — Stopped early
• Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone — Completed
• Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer — Completed
• Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer — Completed
• Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach — Completed
• Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer — Completed
• Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma — Completed
• Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer — Completed